Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

2.14USD
26 May 2017
Change (% chg)

$-0.03 (-1.38%)
Prev Close
$2.17
Open
$2.19
Day's High
$2.24
Day's Low
$2.13
Volume
329,016
Avg. Vol
948,631
52-wk High
$2.35
52-wk Low
$0.59

CPRX.O

Chart for CPRX.O

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $179.30
Shares Outstanding(Mil.): 83.79
Dividend: --
Yield (%): --

Financials

  CPRX.O Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.21 -- --
ROI: -40.68 -8.48 -5.42
ROE: -41.23 -11.31 -4.68

BRIEF-Catalyst Pharmaceuticals Q4 non-gaap loss per share $0.05 excluding items

* Catalyst pharmaceuticals announces fourth quarter and year-end 2016 financial results and provides corporate update

Mar 15 2017

UPDATE 1-Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Mar 15 2017

Catalyst Pharma's neuromuscular drug succeeds in study

Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Mar 15 2017

Catalyst Pharma's neuromuscular drug succeeds in study

March 15 Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.

Mar 15 2017

BRIEF-Catalyst Pharmaceuticals reports positive data from investigator-sponsored trial of firdapse

* Catalyst Pharmaceuticals announces positive data from investigator-sponsored trial of firdapse® in treating musk antibody positive myasthenia gravis

Mar 15 2017

BRIEF-Biocept, Catalyst Pharma to provide liquid biopsy testing for small cell lung cancer

* Biocept and Catalyst Pharmaceuticals collaborate to provide liquid biopsy testing for small cell lung cancer to patients with Lambert Eaton Myasthenic Syndrome (LEMS)

Mar 14 2017

More From Around the Web

Earnings vs. Estimates